Thalidomide-associated arterial thrombosis: Two case reports

Annals of the Academy of Medicine Singapore

Volumn 36, Issue 4, 2007, Pages 304-306

  Altintas, Abdullah ^a   Ayyildiz, Orhan ^a   Atay, A Engin ^a   Cil, Timucin ^a   Isikdogan, Abdurrahman ^a   Muftuoglu, Ekrem ^a  

^a DICLE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; DEXAMETHASONE; THALIDOMIDE; WARFARIN;

ADULT; ANGIOGRAPHY; ARTERY THROMBOSIS; CASE REPORT; CLINICAL FEATURE; DRUG DOSE INCREASE; ECHOCARDIOGRAPHY; HUMAN; LETTER; MALE; MULTIPLE MYELOMA; PHYSICAL EXAMINATION;

EID: 34548179309     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Letter

References (12)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2005;352:1163-73.
2. Rajkumar SV.Thalidomide therapy and deep venous thrombosis in multiple myeloma. Mayo Clin Proc 2005;80:1549-51.
3. Dimopoulos MA, Eleutherakis-Papaiakovou V. Adverse effects of thalidomide administration in patients with neoplastic diseases. Am J Med 2004;117:508-15.
4. Barbui T, Falanga A. Thalidomide and thrombosis in multiple myeloma. J Thromb Haemost 2003;1:421-2.
5. Marks PW, Rosenthal DS. Hematologic manifestations of systemic disease: infection, chronic inflammation, and cancer. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, et al, editors. Hematology Basic Principles and Practice. 4th ed. Philadelphia: Churchill Livingstone, 2005:2573-84.
6. Piette JC, Sbai A, Frances C. Warning thalidomide-thrombotic risk potentially concerns patients with lupus. Lupus 2002;11:67-70.
7. Scarpace SL, Hahn T, Roy H, Brown K, Paplham P, Channan-Khan A, et al. Arterial thrombosis in four patients treated with thalidomide. Leuk Lymphoma 2005;46:239-42.
8. Zangari M, Siegel E, Barlogie B, Anaissie E, Saghafifar F, Fassas A, et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide implications for therapy. Blood 2002;100:1168-71.
9. Schut P, Ebeling P, Buttkereit U, Brandhorst D, Opalka B, Poser M, et al. Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival. Ann Haematol 2005;84:594-600.
10. Bennett CL, Schumock GT, Desai AA, Kwaan HC, Raisch DW, Newlin R, et al. Thalidomide-associated deep vein thrombosis and pulmonary embolism. Am J Med 2002;113:603-6.
11. Zangari M, Barlogie B, Anaissie E, Saghafifar F, Eddlemon P, Jacobson J, et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 2004;126:715-21.
12. Baz R, Li L, Kootke-Marchant K, Srkalovic G, Mcgowan B, Yiannaki E, et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 2005;80:1568-74.